NSCLC Coverage From Every Angle
Editor:
David S. Ettinger, MD
Advertisement
Advertisement

Videos

Jeremy Warner, MD, on Patient Navigation: The Proactive Approach

Johan F. Vansteenkiste, MD, PhD, on NSCLC: Immunotherapy Perspectives

Simron Singh, MD, MPH, on Patient-Centered Care: Measuring Experience

Leora Horn, MD, on NSCLC: The Path Forward for ALK Inhibitors and Immunotherapy

Mark G. Kris, MD, on NSCLC: Juggling Sequence and Agent Choices

Karen Reckamp, MD, on Metastatic NSCLC: Targeted Treatment Updates

A Patient’s Story: NCCN Guidelines for Patients® Helped Me Ask The Right Questions

A Patient’s Story: How NCCN Guidelines for Patients® Helped Me and My Caregiver

Crystal S. Denlinger, MD, and Ann H. Partridge, MD, MPH, on Making Sense of Guidelines and Guidance

Roy S. Herbst, MD, PhD, on Personalized Immunotherapy for Lung Cancer: Expert Perspective

Mollie Reed, MSN, RN, ACNP-BC, on Managing Rash Linked to TKIs

Martin Reck, MD, PhD, on Selecting Immunotherapy

Virginie Westeel, MD, PhD, on Managing Immune-Related Adverse Events Associated With Checkpoint Inhibitor Therapy

Kathrin Milbury, PhD, on Patients With Lung Cancer: Benefits of Yoga

Luis G. Paz-Ares, MD, PhD, on Managing Immune-Related Adverse Events Associated With Checkpoint Inhibitor Therapy

Silvia Formenti, MD, on Combining Immunotherapy and Radiation Therapy

Clemens Grassberger, PhD, on NSCLC: Therapy Sequencing Criteria

Mariano Provencio, MD, PhD, on NSCLC: Results From the NADIM and NORA Trials

Martin Reck, MD, PhD, on NSCLC: Results From Three Key Trials

Pilar Garrido López, MD, PhD, on Immunotherapy in Thoracic Malignancies

Virginie Westeel, MD, PhD, on NSCLC: Results From the IFCT-0302 Trial

Tony Mok, MD, on Oncogene-Addicted NSCLC: Expert Perspective on the Challenges

Alice Tsang Shaw, MD, PhD, and Tony Mok, MD: Results From the ARCHER 1050 Trial

Ramaswamy Govindan, MD, and Yi-Long Wu, MD: Results From the CTONG ADJUVANT Trial

Ramaswamy Govindan, MD, and Jaafar Bennouna, MD: Results From the AvaALL Trial

David S. Ettinger, MD, and Matthew A. Gubens, MD: Immunotherapies for Lung Cancer

David S. Ettinger, MD, and Gregory J. Riely, MD, PhD: The What, When, and How of Biomarker Testing

David S. Ettinger, MD, and Wallace Akerley, MD: Biomarker-Based Treatment Selection

Stephanie Andrews, MS, ANP-BC, on Managing Toxicities of Immunotherapies

David S. Ettinger, MD, on The Why and How of Cancer Treatment Guidelines

Daniel R. Gomez, MD, on Immunotherapy in Lung Cancer and the Value Proposition

Walter J. Curran, MD, on Stage III NSCLC

Benjamin Movsas, MD, and Quynh Nguyen, MD, on Quality of Life and Palliative Care in Lung Cancer

Naiyer A. Rizvi, MD, on Immunotherapy: Beyond Checkpoint Inhibition

The JNCCN Spotlight

Welcome to JNCCN 360

Copyright © 2018 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.